ケイ質砂岩腫瘍の腫瘍抗原同定のプラットフォームから提示された最初のパブリック データ.|First Public Data Presented from Gritstone Oncology’s Tumor Antigen Identification Platform for …

オープンデータ関連のニュースです。

• ケイ質砂岩腫瘍の腫瘍抗原同定のプラットフォームから提示された最初のパブリック データ.|First Public Data Presented from Gritstone Oncology’s Tumor Antigen Identification Platform for …

日本語

TranslateApiException: Cannot find an active Azure Market Place Translator Subscription associated with the request credentials. : ID=0759.V2_Json.Translate.51A68B3C
続きを読む…

English

Gritstone Oncology, a next-generation personalized cancer immunotherapy company, today announced the first reported data supporting its novel approach to tumor-specific neoantigen (TSNA) identification through integrated tumor tissue analysis and deep learning. The data are being presented in the Tumor Antigens and Adaptive Immunity poster session on Sunday, April 2 from 1:00 – 5:00 PM EDT at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C. “For years, cancer immunotherapy has been one of the most exciting fields in oncology research, yet it also poses some of the greatest challenges,” said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone Oncology.
Read more…